Next Generation Sequencing Panel for Hereditary Colon Cancer [Featured Topic]

Mayo Medical Laboratories is pleased to announce the availability of our Hereditary Colon Cancer Multi-Gene Panel.

This panel uses next generation sequencing (NGS), array comparative genomic hybridization (aCGH), and other technologies to evaluate for germline mutations in 17 genes known to be associated with an increased risk for colon cancer development.

Below, Matthew Ferber, Ph.D., Director of Mayo Clinic's Molecular Genetics Laboratory, discusses Mayo Clinic's Hereditary Colon Cancer Multi-Gene Panel, which uses next generation sequencing (NGS), array comparative genomic hybridization (aCGH), and other technologies to evaluate for germline mutations in 17 genes known to be associated with an increased risk for colon cancer development.

More information on this new panel can be found here.

mayocliniclabs

Mayo Medical Laboratories

This post was authored by the Marketing Team at Mayo Medical Laboratories.